Evidence map›Paper›PMID 34285457›Full record

ArticleClinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology2021

Two girls with a neonatal screening-negative 21-hydroxylase deficiency requiring treatment with hydrocortisone for virilization in late childhood.

Shinsuke Onuma, Tomoya Fukuoka, Yoko Miyoshi, Miho Fukui, Yoshinori Satomura, Kie Yasuda, Takeshi Kimura, Makiko Tachibana, Kazuhiko Bessho, Takehisa Yamamoto and 5 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Shinsuke OnumaDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Tomoya FukuokaDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoko MiyoshiDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Miho FukuiDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoshinori SatomuraDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Kie YasudaDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Takeshi KimuraDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Makiko TachibanaDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Kazuhiko BesshoDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Takehisa YamamotoDepartment of Pediatrics, Minoh City Hospital, Osaka, Japan.
Hiroyuki TanakaDepartment of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Japan.
Noriyuki KatsumataDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
Maki FukamiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
Tomonobu HasegawaDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Keiichi OzonoDepartment of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Osaka University · JPOsaka City University · JPNational Center For Child Health and Development · JPKeio University · JPMinoh City Hospital · JPOkayama Saiseikai General Hospital · JPOsaka Shoin Women's University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we report two girls with a neonatal screening (NS)-negative 21-hydroxylase deficiency (21-OHD) requiring treatment with hydrocortisone due to virilization that developed in late childhood. Patient 1 was born prematurely on the 30th gestational week with normal external genitalia at birth. She passed the NS for 21-OHD. At 6 yr of age, she was referred to a hospital for evaluation of premature pubarche and clitoromegaly. Her diagnosis was central precocious puberty, and GnRH agonist was initiated. However, her symptoms did not improve despite treatment for over 4 years. She was then referred to our hospital where she was diagnosed with 21-OHD. Although she was started on hydrocortisone therapy, her adult height reached only 140 cm (-3.4 SD). Patient 2 was delivered at 37 weeks of gestation and passed the NS for 21-OHD. She was referred to a hospital because of premature pubarche at the age of 6 yr. She was diagnosed with 21-OHD, and hydrocortisone replacement therapy was initiated. Her present height at 13 yr of age is 148 cm (-1.3 SD). These cases reminded us that the possibility of 21-OHD should be considered when patients show premature pubarche or precocious puberty, even if they passed the NS test for 21-OHD.

Indexed as

21-hydroxylase deficiencycongenital adrenal hyperplasianeonatal screeningpremature birthsecondary central precocious puberty

Identifiers

PMID34285457
PMCPMC8267553
OpenAlexW3179361163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.